Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis

BACKGROUND/OBJECTIVES: Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild‐to‐moderate atopic dermatitis (AD). This pooled post hoc analysis of two phase 3 trials (NCT02118766, NCT02118792) assessed improvement and time to improvement in Investigator&#...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pediatr Dermatol
Main Authors: Eichenfield, Lawrence F., Yosipovitch, Gil, Stein Gold, Linda F., Kalabis, Mizuho, Zang, Chuanbo, Vlahos, Bonnie, Sanders, Paul, Myers, Daniela E., Bushmakin, Andrew G., Cappelleri, Joseph C., Olivadoti, Melissa, Paller, Amy S.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7756882/
https://ncbi.nlm.nih.gov/pubmed/32981097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pde.14328
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares